February 2021

AUROBINDO PHARMA LTD (APL) is a growing Indian multinational pharmaceutical manufacturing firm with turnover of over US$2.8 Billion revenues for 2018-19, with presence in more than 34 countries fronted presence with products exported to 155 nations. 

Biotech Consortium India Limited (BCIL) is a public limited company, promoted by the Department of Biotechnology (DBT), Ministry of Science and Technology, Government of India and set up by All India Financial Institutions including IDBI, ICICI, IFCI, UTI and IFCI Venture Capital Funds Limited. BCIL was incorporated under the Companies Act 1956(Now Company Act, 2013) in 1990 with government in advisory role, development banks as major funding agency.

Amoli Organics Sites are CGMP and SHE compliant USFDA, ANVISA, EDQM, COFEPRIS- Cleared. Company’s Presence is in USA, EUROPE, JAPAN, RUSSIA, SOUTH EAST ASIA, MIDDLE EAST AND LATAM. Amoli has a successful track record in the pharmaceutical and allied industry. Making a beginning as a manufacturer of API"s and Intermediates.

Founded in 1849, Pfizer is the world's premier biopharmaceutical company taking new approaches to better health. We discover, develop, manufacture and deliver quality, safe and effective prescription medicines to treat and help prevent disease for both people and animals. We also partner with healthcare providers, governments and local communities around the world to expand access to our medicines and to provide better quality health care and health system support.

Post : Specialist - Quality Projects

ACCF (Assam Cancer Care Foundation) is a section 8 company and a joint initiative of the Government of Assam and the Tata Trusts, established to create a three-tier comprehensive model serving all sections of society. ACCF is coming up with digitally-enabled, modern cancer hospitals with state-of-the-art technology, which includes radiation equipment, in Tezpur and Barpeta, Assam. These hospitals have an occupancy of 135 beds in Barpeta, and 44 beds in Tezpur.

Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs for the treatment of HIV/AIDS. Backed by over 25 years of expertise in the pharmaceutical industry, Hetero’s strategic business areas spread across APIs, Generics, Biosimilars, Custom Pharmaceutical services and Branded Generics.

In a joint press briefing today together with German Health Minister Jens Spahn, Minister-President of North Rhine-Westphalia, Armin Laschet, and Chief Executive Officer of CureVac N.V., Franz-Werner Haas, Member of the Board of Management, Bayer AG and President of the Bayer’s Pharmaceuticals Division, Stefan Oelrich, made the following statement  “Following discussions with the German government it has become clear that current manufacturing capacities for vaccines need to be increased, particularly for potential variants of the SARS-CoV-2 virus.

Eli Lilly and Company has partnered with local health systems to launch dedicated infusion center locations serving central, northern, and now southern Indiana that are intended to provide Hoosiers with access to important COVID-19 treatments.  Multiple neutralizing antibody therapies, administered via intravenous infusion, have been granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) for the treatment of mild to moderate COVID-19 in high-risk patients.

Eisai Co., Ltd announced that Eisai Korea Inc., Eisai’s subsidiary in South Korea, has launched the Parkinson’s disease treatment Equfina® (safinamide mesilate, “safinamide”). This is the first launch of Equfina in the Asian region excluding Japan.